BREAST CANCER

Breast Cancer

Jane Lowe Meisel, MD, reviewed systemic therapy options for treating patients with breast cancer with a group of physicians during a&nbsp;<em>Targeted Oncology&nbsp;</em>live case-based peer perspectives discussion. Meisel explained the treatment considerations she makes for treating patients with breast cancer during the dinner event in terms of 2 case studies.

General Cancer

The SOLAR-1 findings were presented during a satellite symposium at the 2019 European Society for Medical Oncology Breast Cancer Annual Congress in Berlin, Germany.&nbsp;The trial demonstrated the role of&nbsp;<em>PIK3CA&nbsp;</em>as a predictive marker for alpelisib&rsquo;s clinical efficacy, said Peter A. Fasching, MD, associate professor of gynecology and obstetrics at Friedrich-Alexander University of Erlangen-Nuremberg in Germany, during the symposium.

Preventive strategies for severe diarrhea associated with adjuvant treatment with neratinib improved tolerability for the agent when patients received budesonide or colestipol-with-loperamide prophylaxis, according to findings from the CONTROL study.

Biomarker expansion has enjoyed a boom since 2006, with patient incidence of positive biomarkers reaching up to 50% in non&ndash;small cell lung cancer and melanoma and 25% in acute myeloid leukemia and myelodysplastic syndromes, according&nbsp; to the <em>Global Oncology Trends 2018</em> report.

Patients with HER2-positive metastatic breast cancer receiving frontline HER2-targeted therapy with pertuzumab&nbsp;and trastuzumab followed by T-DM1 in the second-line setting may be able to forgo chemotherapy without increasing the risk of early death, according to results from the phase II PERNETTA trial.